TAK-778

• Description:

  TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Drug Derivative; IGF-1R; MMP; Phosphatase; TGF-β Receptor

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease; Others; Protein Tyrosine Kinase/RTK; TGF-beta/Smad

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/TAK-778.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (NC1=CC=C (CP (OCC) (OCC) =O) C=C1) [C@@H] (C2) S[C@@H] (C) C (C3=C2C=C4OCOC4=C3) =O

• Molecular Formula:

  C24H28NO7PS

• Molecular Weight:

  505.52

• Precautions:

  P264-P270-P330-P501

• References & Citations:

  [1]Rosa AL, et al. TAK-778 enhances osteoblast differentiation of human bone marrow cells via an estrogen-receptor-dependent pathway. J Cell Biochem. 2004 Mar 1;91 (4) :749-55.|[2]Notoya K, et al. Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J Pharmacol Exp Ther. 1999 Sep;290 (3) :1054-64.|[3]Cai M, et al. TAK-778 induces osteogenesis in ovariectomized rats via an estrogen receptor-dependent pathway. J Bone Miner Metab. 2011 Mar;29 (2) :168-73.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  180185-61-9